Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 2/20 | 0.31 |
| ▸ | CCND1 | P24385 | 2/20 | 0.31 |
| ▸ | CCND3 | P30281 | 2/20 | 0.31 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25272678 | 1.00 | JAK1 (0.32) | JAK1PIK3CACDK4CCND1CCND3 | |
| SCHEMBL25225259 | 1.00 | JAK1 (0.32) | JAK1PIK3CACDK4CCND1CCND3 | |
| SCHEMBL25226337 | 0.92 | ATR (0.34) | JAK1PIK3CAMAPK1 | |
| SCHEMBL31458631 | 0.86 | JAK1 (0.33) | JAK1PIK3CAMAPK1 | |
| SCHEMBL25223683 | 0.81 | JAK1 (0.31) | JAK1 | |
| SCHEMBL25227742 | 0.79 | JAK1 (0.34) | JAK1PIK3CACDK4CCND1CCND3 | |
| SCHEMBL25278143 | 0.75 | JAK2 (0.35) | JAK1MAPK1 | |
| SCHEMBL30485991 | 0.74 | PIK3CA (0.38) | PIK3CACDK4CCND1CCND3CDK6 | |
| SCHEMBL31458674 | 0.74 | JAK2 (0.34) | JAK1MAPK1 | |
| SCHEMBL25277898 | 0.73 | ATR (0.35) | PIK3CAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192706-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-06-22 | — | — | US | claimed |
| US-20230192706-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| US-20230192706-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192706-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CDK2, CCNI, CDK1 | JAK1 605/4885PIK3CA 323/4885CDK4 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.